Is Mounjaro a GLP-1 medicine — and why does the distinction matter?

You've read 'GLP-1' everywhere, then Mounjaro appeared and the term no longer quite fit

Most of the weight-loss medicines that dominate headlines (semaglutide in particular) work by mimicking a single gut hormone called GLP-1 (glucagon-like peptide-1). That hormone is released after eating; it slows the rate at which food leaves the stomach, quiets appetite signals in the brain, and nudges the pancreas to release insulin in response to glucose. Medicines that copy its action are called GLP-1 receptor agonists.

Mounjaro does all of that. But tirzepatide, the active ingredient in Mounjaro, also activates a second receptor: GIP, or glucose-dependent insulinotropic polypeptide. GIP is a gut hormone released even before food fully digests, and it has its own effects on appetite, fat storage and how the body handles energy. Activating both pathways simultaneously is the defining feature of tirzepatide, and if you want to go deeper on the receptor science, our page on whether tirzepatide is a GLP-1 covers it in full. You can read more about the receptor science on the tirzepatide overview page.

So: is Mounjaro a GLP-1? Partly, yes, it activates the GLP-1 receptor. But calling it simply a GLP-1 drug undersells what it actually does. The more precise label is dual GIP and GLP-1 receptor agonist, and it is the only medicine of that type licensed for weight management in the UK.

What the GIP receptor adds, and why researchers think it matters

When semaglutide's results were published, the clinical community was impressed: an average of roughly 15% body-weight reduction over 68 weeks in the STEP 1 trial, as reported in the New England Journal of Medicine. Then tirzepatide's SURMOUNT-1 data arrived, showing around 20–21% average reduction at the highest dose over a similar timeframe, with some participants losing considerably more. The question everyone asked was: what is the GIP contribution doing?

The honest answer is that the full mechanism is still being studied. What the trial data shows is that the combination produces greater average weight loss than GLP-1 stimulation alone, and that tolerability is broadly similar, the side-effect profile is still dominated by gastrointestinal effects like nausea, loose stools and reduced appetite, particularly in the early weeks of treatment. The GIP receptor may also dampen some of the nausea driven by GLP-1 activation, though this is not yet settled science.

For anyone comparing treatments, the Mounjaro treatment page covers the licensed doses, the titration schedule and what the clinical process at nume looks like in practice.

How NICE and the NHS classify Mounjaro, and who it's licensed for

NICE appraised tirzepatide in December 2024 (TA1026) and recommended it for adults with a BMI of 35 or above alongside at least one weight-related condition such as type 2 diabetes, high blood pressure or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The NHS is rolling this out in phases, eligibility on the NHS is currently restricted and depends on BMI, number of qualifying conditions, and which phase your integrated care board has reached.

Privately, the licensed criteria are broader: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. A prescriber still reviews the full picture. BMI meeting the threshold is the starting point, not the finish line. The weight-loss treatments page has the detail on the consultation process and what's needed to get started.

It's also worth noting that Mounjaro is prescribed for type 2 diabetes as well as weight management; the dual receptor mechanism has meaningful effects on blood-sugar regulation too. These are separate licensed indications, and a prescriber considers which applies to you.

Is tirzepatide the same thing as a GLP-1 drug, and does the label matter for your decision?

Practically speaking, if you've been researching how Mounjaro relates to GLP-1 treatments, you're in the right territory. The treatments sit in the same clinical family, they're taken the same way (once-weekly injection), and the conversation about suitability happens the same way, with a prescriber who knows your medical history.

Where the label matters is in understanding why tirzepatide's results differ from semaglutide's, and why clinicians and NICE treat them as distinct options rather than interchangeable ones. The head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, showed tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks. That said, which treatment suits a given person is a clinical call, not a marketing one.

One question our prescribers hear regularly: does being on a GLP-1 or dual-agonist medicine affect other things, contraception, for instance, or HRT? It can. The absorption of oral contraceptives may be affected during the first four weeks of tirzepatide and after each dose increase; our FAQs address this, and your prescriber will flag it at consultation. If cost is a consideration, our page on taking Mounjaro on finance explains the payment options available. The about us page explains who our clinical team are and how oversight works.